Physician profile
David D Holstein
NPI 1518987585
$6,824.43
in general payments reported to CMS, 2019-2025
42 companies · $50.05 in 2025
The $50.05 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $1,825 · 2021: $2,021 · 2022: $727 · 2023: $565 · 2024: $285 · 2025: $50.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.29 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,140.69 | 2019-2025 | |
| Biogen, INC. | $613.14 | 2019-2023 | Tysabri, Vumerity |
| Allergan, INC. | $607.14 | 2019-2022 | |
| Abbvie INC. | $488.91 | 2021-2022 | |
| Sk Life Science, INC. | $412.73 | 2020-2023 | Xcopri |
| Ucb, INC. | $345.87 | 2019-2021 | |
| Amgen INC. | $305.32 | 2019-2023 | Aimovig |
| Emd Serono, INC. | $261.58 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $219.63 | 2019-2022 | |
| Genzyme Corporation | $217.25 | 2019-2022 | |
| Csl Behring | $216.89 | 2020-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $194.24 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $183.04 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $154.24 | 2019-2020 | |
| Boston Scientific Corporation | $125.00 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.